| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| PERLMUTTER ROGER M | Chief Executive Officer and Director, Director | C/O EIKON THERAPEUTICS, INC., 230 HARRIET TUBMAN WAY, MILLBRAE | /s/ Benjamin Thorner, Attorney-in-Fact | 10 Feb 2026 | 0001184228 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EIKN | Common Stock | Conversion of derivative security | +284,857 | 284,857 | 06 Feb 2026 | See Footnote | F1, F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EIKN | Series A-1 Preferred Stock | Conversion of derivative security | -1,268,891 | -100% | 0 | 06 Feb 2026 | Common Stock | 170,143 | See Footnote | F1, F3 | |||
| transaction | EIKN | Series D Preferred Stock | Conversion of derivative security | -855,512 | -100% | 0 | 06 Feb 2026 | Common Stock | 114,714 | See Footnote | F2, F3 |
| Id | Content |
|---|---|
| F1 | The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. |
| F2 | The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. |
| F3 | The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. |
Chief Executive Officer and Director